Board Spotlight: Kara Engley

May 25, 2022

Kara Engley, Controller, Camgill Development Corporation

Kara is the the Controller for Camgill Development Corporation, and has been working Camgill, and the CRE industry, for 14 years now. She currently supports CREW as the Treasurer.

What was your path to joining CREW and what has been the biggest benefit of being a part of the organization?

Kara learned of CREW through her CFO and CREW Past-President Melanie Ducholke. She says that “the greatest benefit of CREW, has been the confidence that comes with having a network of supportive women throughout the industry.”

Why did you to take your involvement in CREW to the next level?

Kara took the next step to become more involved with CREW when she decided to really get to know the other members.

What are the elements of working in the Commercial Real Estate Industry that excite you the most?

Within the Commercial Real Estate Industry, Kara is excited by the variety of transactions she works on day to day, and the different information you need to analyse and evaluate on a regular basis.

Tell us about your greatest professional achievement to-date.

Kara’s greatest professional achievement was completing her CPA in 2016.

How are members of CREW impacting the Commercial Real Estate network and elevating our industry?

“By supporting and celebrating women and their accomplishments throughout a typically male-dominated industry.”

Share one (or two) pieces of advice for how to build a successful career or achieve a challenging professional goal.

Kara’s advice for building a career in real estate would be to “ask questions and accept advice from mentors that have been where you are, and try every day to move a little bit outside your comfort zone.”

What’s one thing — either industry-related or not — you learned in the last month?

“In the 1960's, it had been a female pharmacologist and physician (Dr Frances Oldham Kelsey) that prevented the distribution of Thalidomide in the US. The file was given to her as an entry-level researcher because it was assumed to be a simple review, as it was so widely prescribed in Europe and thought to have no side effects.  She remained firm that there was not enough testing, and refused to approve it, saving thousands of children from potentially devastating birth defects.”